RENEGADE THERAPEUTICS Trademark

Trademark Overview


On Wednesday, October 5, 2022, a trademark application was filed for RENEGADE THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the RENEGADE THERAPEUTICS trademark a serial number of 97620671. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, July 31, 2024. This trademark is owned by ReNAgade Therapeutics Management Inc.. The RENEGADE THERAPEUTICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy containing polypeptide encoding nucleic acids for the prevention and/or treatment of rare diseases, cancers, diabetes, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitut...

Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, and chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, and for use in the manufacture of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and...

Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering, genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy and cell therapy, research, development and testing services in the field of pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics in the nature of linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customizati...
renegade therapeutics

General Information


Serial Number97620671
Word MarkRENEGADE THERAPEUTICS
Filing DateWednesday, October 5, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, July 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements


Goods and ServicesPharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy containing polypeptide encoding nucleic acids for the prevention and/or treatment of rare diseases, cancers, diabetes, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for in vitro, in vivo, or ex vivo delivery to a cell, organ, tissue, or body; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of infectious diseases, blood disorders, diabetes, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for the prevention of osteoporosis; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics for the treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral infections; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for treating diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for use in chemotherapy; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, namely, antivirals; Vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; veterinarian vaccine preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral and joint diseases
Goods and ServicesBiochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, and chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, and for use in the manufacture of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Reagents for testing sterility of pharmaceuticals; Diagnostic reagents for scientific or research use; chemicals for use in biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use; Biochemical catalysts; Biochemical preparations for scientific purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations used in science; Nucleic acid for laboratory use; Protein in raw material form for scientific and medical research; Reagents for research purposes; Reagents for scientific and research use; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Antioxidants for use in the manufacture of pharmaceuticals; Biochemicals for in vitro, in vivo, and ex vivo scientific use; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Cells for scientific, laboratory or medical research; Chemical additives for use in the manufacture of pharmaceuticals; Chemicals for use in the biochemical and chemical industry; Chemicals for use in the purification of proteins for in vitro use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Enzymes for use in protein hydrolysis; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Plant extracts for use in the manufacture of pharmaceuticals; Protein arrays and nucleotide arrays for scientific and medical research; Reagents for scientific or medical research use
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesScientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering, genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy and cell therapy, research, development and testing services in the field of pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics in the nature of linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Medical and scientific research in the field of cancer treatment and diagnosis; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of nucleic acids, inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Pharmaceutical research and development; Product research and development; Scientific research and development; Vaccine research and development

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateSaturday, October 22, 2022
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, October 22, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, October 22, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameReNAgade Therapeutics Management Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Party NameReNAgade Therapeutics Management Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Saturday, October 8, 2022NEW APPLICATION ENTERED
Saturday, October 22, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 19, 2023ASSIGNED TO EXAMINER
Monday, August 7, 2023NON-FINAL ACTION WRITTEN
Monday, August 7, 2023NON-FINAL ACTION E-MAILED
Monday, August 7, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 4, 2023ASSIGNED TO EXAMINER
Monday, November 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 7, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 20, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 20, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, February 20, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 31, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 31, 2024SOU EXTENSION 1 FILED
Wednesday, July 31, 2024SOU EXTENSION 1 GRANTED
Tuesday, February 20, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED